Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell Carcinoma

计划入组 220 人 · 首次发布于 2026 年 9 月 10 日

Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma

计划入组 51 人 · 首次发布于 2021 年 1 月 22 日

Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002)

计划入组 43 人 · 首次发布于 2021 年 10 月 28 日

NANT Squamous Cell Carcinoma Vaccine

GPR87 antagonists (squamous cell carcinoma)

NUCC-0227383

Tres-Or Resources Ltd

Oral-B Laboratories

United States

Philips Oral Healthcare

United States

FluoGuide's FG001 Demonstrates Positive Phase 2 Data in Head and Neck Cancer Surgery

ORATOR Trial: Radiotherapy and Transoral Robotic Surgery Show Similar Outcomes in Oropharyngeal Cancer

Non-Invasive Brush Biopsy Test Detects Oral Squamous Cell Carcinoma with 95.5% Accuracy in Under One Hour